Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, Double-Blind Study of Ceftobiprole Medocaril vs Ceftriaxone ± Linezolid in Hospitalized Community-Acquired Pneumonia
2006-000835-84Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftobiprole medocaril in community-acquired pneumonia (CAP) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical cure rate at test-of-cure visit. Started Jun 2006; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2006-000835-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000835-84.